methyl salicylate has been researched along with Acute Pain in 1 studies
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990
methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.
Acute Pain: Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mean migraine duration was 18." | 3.11 | A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. ( Arkuszewski, M; Ecochard, L; Kim, BK; Li, Z; Lian, Y; Su, W; Wan, Q; Wang, H; Wang, SJ; Wen, S; Yin, F; Yu, S; Yu, T; Zhou, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, S | 3 |
| Kim, BK | 3 |
| Wang, H | 3 |
| Zhou, J | 3 |
| Wan, Q | 3 |
| Yu, T | 3 |
| Lian, Y | 3 |
| Arkuszewski, M | 3 |
| Ecochard, L | 3 |
| Wen, S | 3 |
| Yin, F | 3 |
| Li, Z | 3 |
| Su, W | 3 |
| Wang, SJ | 3 |
1 trial available for methyl salicylate and Acute Pain
| Article | Year |
|---|---|
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |